Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-mechanism study of oral hedgehog inhibitor GDC-0449 in resectable pancreatic ductal adenocarcinoma
2010-018776-24Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vismodegib in pancreatic adenocarcinoma (PDAC), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Gli signalling inhibition in stromal tissue. Started Oct 2010; status: terminated.
02
Drugs
vismodegib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2010-018776-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018776-24.